AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Protara Therapeutics, Inc.
Video analysis: TARA
All videosNo video analysis for this stock yet. Request one from our team.
News: TARA
Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 2:00 pm ET.
Bank of America Corp DE Buys 430,014 Shares of Protara Therapeutics, Inc. $TARA
Bank of America Corp DE grew its stake in shares of Protara Therapeutics, Inc. (NASDAQ: TARA) by 86.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 925,918 shares of the company's stock after buying an additional 430,014 shares during
Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline
Protara Therapeutics is rated Buy, with a risk-adjusted fair value of $9.96 per share versus the current ~$4 price. TARA-002 targets NMIBC and Lymphatic Malformations; orphan drug indications offer significant upside, despite NMIBC's competitive landscape and lower CR rates. IV Choline Chloride, targeting severe choline deficiency in parenteral nutrition patients, could generate substantial revenue if approved, with pivotal data expected in 2026.
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Moderate Buy” from Brokerages
Shares of Protara Therapeutics, Inc. (NASDAQ: TARA - Get Free Report) have received an average rating of "Moderate Buy" from the eight research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average
What Makes Protara Therapeutics (TARA) a New Buy Stock
Protara Therapeutics (TARA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ROYAL CARIBBEAN GROUP APPOINTS TARA BUNCH TO BOARD OF DIRECTORS
MIAMI, July 20, 2026 /PRNewswire/ -- Royal Caribbean Group (NYSE: RCL) today announced the appointment of Tara Bunch, former Senior Vice President and Global Head of Operations at Airbnb, to its Board of Directors. Bunch brings more than three decades of experience scaling global technology organizations, leading complex operations, strengthening customer experience, and advancing digital transformation across highly recognized consumer brands.
Tradeweb Launches TARA, an AI-Powered Research Assistant for Institutional Credit Trading
NEW YORK--(BUSINESS WIRE)--Tradeweb Markets Inc. (Nasdaq: TW), a global leader in electronic trading across asset classes, today announced the launch of TARA (Tradeweb AI Research Assistant), a conversational AI-powered assistant designed to help institutional U.S. credit market participants transform trading data into actionable real-time market intelligence and trading insights. Embedded directly within the Tradeweb institutional platform, TARA enables users to query trading activity, market.
